EMAIL THIS PAGE TO A FRIEND

Current drug delivery

Design and in vitro evaluation of a novel vaginal drug delivery system based on gelucire.


PMID 19450222

Abstract

Carbamazepine indicated for the control of epilepsy, undergoes extensive hepatic first-pass metabolism after oral administration. A vaginal dosage form of carbamazepine is not commercially available. Conventional suppository having poor retention in the vaginal tract, as they are removed in a short time by the tract's self-cleansing action, having poor patient compliance. To overcome such problems, delivery system with mucoadhesive polymers polyox WSR N-60K and Ucarflock 302 that prolong drug permanence on the vaginal mucosa were developed. In the present study the suitability of gelucires to formulate vaginal pesseries was investigated. The possible modification of carbamazepine release kinetics by using gelucires blends and hydrophilic additives in the pesseries was evaluated. It was observed that among gelucire grades melting point higher than 37 degrees C, the release rate proved to be highly dependant on HLB value and matrix composition. In most of the formulations carbamazepine release occurred by disintegration and erosion of the matrices which is depending upon the vehicle employed. The aging study revealed that the formulations containing G50/13 and G50/13-G44/14 blends undergo some changes during one year of shelf aging. From the results obtained it can be concluded that different gelucire grades and their blends along with hydrophilic polymer could be successesively used to formulate prolong release carbamazepine pesseries.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

91462
Kollisolv® PEG E 300
06855
Kollisolv® PEG E 400
P3015
Poly(ethylene glycol), average mol wt 200
88440
Poly(ethylene glycol), BioUltra, 200
81162
Poly(ethylene glycol), tested according to Ph.Eur., 300
202371
Poly(ethylene glycol), average Mn 300
90878
Poly(ethylene glycol), BioUltra, 300
91893
Poly(ethylene glycol), BioUltra, 400
202398
Poly(ethylene glycol), average Mn 400
81172
Poly(ethylene glycol), tested according to Ph.Eur., 400
P3265
Poly(ethylene glycol), average mol wt 400
202401
Poly(ethylene glycol), average Mn 600, waxy solid (moist)
87333
Poly(ethylene glycol), BioUltra, 600
P3515
Poly(ethylene glycol), average Mn 950-1,050
81188
Poly(ethylene glycol), BioUltra, 1,000
81189
Poly(ethylene glycol), BioUltra, for molecular biology, 1,000
03395
Poly(ethylene glycol), tested according to Ph.Eur., 1,000
P7777
Poly(ethylene glycol), Hybri-Max, mol wt 1,300-1,600, waxy solid, BioReagent, suitable for hybridoma
202436
Poly(ethylene glycol), average Mn 1,305-1,595, waxy solid
P5402
Poly(ethylene glycol), average mol wt 1,450
81210
Poly(ethylene glycol), average Mw 1,500
81214
Poly(ethylene glycol), tested according to Ph.Eur., 1,500
86101
Poly(ethylene glycol), BioUltra, 1,500
84797
Poly(ethylene glycol), BioUltra, 2,000
81227
Poly(ethylene glycol), BioUltra, 3,000
295906
Poly(ethylene glycol), average Mn 2,050, chips
03997
Poly(ethylene glycol), tested according to Ph.Eur., 3,000
P2906
Poly(ethylene glycol), Hybri-Max, mol wt 3,000-3,700, waxy solid, BioReagent, suitable for hybridoma
202444
Poly(ethylene glycol), average Mn 3,350, powder
88276
Poly(ethylene glycol), BioUltra, 3,350